BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 29764592)

  • 41. Epidermal growth factor receptor mutations: effect on volume doubling time of non-small-cell lung cancer patients.
    Nakamura R; Inage Y; Tobita R; Mori K; Numata T; Yanai H; Endo T; Ohtani H; Satoh H; Yuzawa K; Koizumi M; Ueki H
    J Thorac Oncol; 2014 Sep; 9(9):1340-4. PubMed ID: 24481317
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Influencing cancer growth].
    GUGGISBERG
    Gynaecologia; 1948 Apr; 125(4):208-10. PubMed ID: 18915913
    [No Abstract]   [Full Text] [Related]  

  • 43. The Molecular Mechanism of Metabolic Remodeling in Lung Cancer.
    Chang L; Fang S; Gu W
    J Cancer; 2020; 11(6):1403-1411. PubMed ID: 32047547
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Analysis of the First Diagnosis Symptom and Its Influencing Factors in 500 Patients with Lung Cancer].
    Zhang X; Xing P; Hao X; Li J
    Zhongguo Fei Ai Za Zhi; 2018 May; 21(5):408-412. PubMed ID: 29764592
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Driven Gene in Patients with Lung Squamous Cell Carcinoma: 
Analysis of Clinicopathologic Characteristics and Prognosis].
    Zhang T; Li J
    Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):648-652. PubMed ID: 27760592
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma.
    Kim MH; Shim HS; Kang DR; Jung JY; Lee CY; Kim DJ; Lee JG; Bae MK; Kim HR; Lim SM; Kim EY; Park JS; Chung KY; Kim HJ; Kim JH; Cho BC
    Lung Cancer; 2014 Mar; 83(3):389-95. PubMed ID: 24462463
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT.
    Choi H; Paeng JC; Kim DW; Lee JK; Park CM; Kang KW; Chung JK; Lee DS
    Lung Cancer; 2013 Mar; 79(3):242-7. PubMed ID: 23261227
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma.
    Park J; Kobayashi Y; Urayama KY; Yamaura H; Yatabe Y; Hida T
    PLoS One; 2016; 11(8):e0161081. PubMed ID: 27518729
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
    Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
    Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cancer Statistics, 2017.
    Siegel RL; Miller KD; Jemal A
    CA Cancer J Clin; 2017 Jan; 67(1):7-30. PubMed ID: 28055103
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cancer statistics in China, 2015.
    Chen W; Zheng R; Baade PD; Zhang S; Zeng H; Bray F; Jemal A; Yu XQ; He J
    CA Cancer J Clin; 2016; 66(2):115-32. PubMed ID: 26808342
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).
    Shi Y; Au JS; Thongprasert S; Srinivasan S; Tsai CM; Khoa MT; Heeroma K; Itoh Y; Cornelio G; Yang PC
    J Thorac Oncol; 2014 Feb; 9(2):154-62. PubMed ID: 24419411
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.
    Beau-Faller M; Prim N; Ruppert AM; Nanni-Metéllus I; Lacave R; Lacroix L; Escande F; Lizard S; Pretet JL; Rouquette I; de Crémoux P; Solassol J; de Fraipont F; Bièche I; Cayre A; Favre-Guillevin E; Tomasini P; Wislez M; Besse B; Legrain M; Voegeli AC; Baudrin L; Morin F; Zalcman G; Quoix E; Blons H; Cadranel J
    Ann Oncol; 2014 Jan; 25(1):126-31. PubMed ID: 24285021
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness of computed tomography screening for lung cancer in the United States.
    McMahon PM; Kong CY; Bouzan C; Weinstein MC; Cipriano LE; Tramontano AC; Johnson BE; Weeks JC; Gazelle GS
    J Thorac Oncol; 2011 Nov; 6(11):1841-8. PubMed ID: 21892105
    [TBL] [Abstract][Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.